| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Disease Management | 17 | 2016 | 143 | 2.670 |
Why?
|
| Quality of Health Care | 20 | 2021 | 346 | 1.860 |
Why?
|
| Propensity Score | 6 | 2016 | 90 | 1.510 |
Why?
|
| Program Evaluation | 10 | 2012 | 236 | 1.410 |
Why?
|
| Patient Readmission | 4 | 2023 | 161 | 1.270 |
Why?
|
| Research Design | 7 | 2012 | 393 | 1.220 |
Why?
|
| Humans | 103 | 2024 | 18058 | 1.180 |
Why?
|
| Quality Indicators, Health Care | 15 | 2018 | 197 | 1.070 |
Why?
|
| Medicare Part C | 8 | 2022 | 22 | 1.040 |
Why?
|
| Hospitals | 6 | 2014 | 79 | 1.010 |
Why?
|
| Physicians | 10 | 2018 | 143 | 1.010 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 3 | 0.980 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 8 | 0.970 |
Why?
|
| Health Services Research | 10 | 2019 | 271 | 0.910 |
Why?
|
| Aftercare | 1 | 2023 | 49 | 0.890 |
Why?
|
| Practice Patterns, Physicians' | 10 | 2022 | 351 | 0.870 |
Why?
|
| Models, Statistical | 3 | 2016 | 184 | 0.860 |
Why?
|
| Male | 55 | 2024 | 10173 | 0.840 |
Why?
|
| Episode of Care | 3 | 2013 | 14 | 0.840 |
Why?
|
| Regression Analysis | 11 | 2015 | 319 | 0.820 |
Why?
|
| Female | 60 | 2024 | 12838 | 0.790 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 289 | 0.790 |
Why?
|
| Middle Aged | 46 | 2024 | 8073 | 0.720 |
Why?
|
| Medicare | 9 | 2022 | 206 | 0.690 |
Why?
|
| Quality Assurance, Health Care | 10 | 2013 | 188 | 0.670 |
Why?
|
| Delivery of Health Care | 6 | 2023 | 445 | 0.660 |
Why?
|
| Aged | 43 | 2024 | 6258 | 0.660 |
Why?
|
| United States | 41 | 2022 | 4119 | 0.650 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 742 | 0.650 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 613 | 0.640 |
Why?
|
| Physicians, Primary Care | 2 | 2016 | 75 | 0.610 |
Why?
|
| Causality | 2 | 2015 | 43 | 0.560 |
Why?
|
| Health Care Costs | 4 | 2012 | 253 | 0.550 |
Why?
|
| Healthcare Disparities | 4 | 2018 | 205 | 0.520 |
Why?
|
| Risk Assessment | 4 | 2016 | 1137 | 0.520 |
Why?
|
| Patient Selection | 2 | 2008 | 194 | 0.510 |
Why?
|
| Managed Care Programs | 9 | 2022 | 356 | 0.500 |
Why?
|
| Fetal Death | 1 | 2014 | 9 | 0.500 |
Why?
|
| Obstetric Labor Complications | 1 | 2014 | 14 | 0.500 |
Why?
|
| Skilled Nursing Facilities | 1 | 2014 | 8 | 0.500 |
Why?
|
| Obstetrics | 1 | 2014 | 24 | 0.490 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2014 | 34 | 0.490 |
Why?
|
| Hospitalization | 4 | 2023 | 813 | 0.470 |
Why?
|
| Costs and Cost Analysis | 3 | 2012 | 89 | 0.470 |
Why?
|
| Retrospective Studies | 15 | 2024 | 2498 | 0.450 |
Why?
|
| Ethnic Groups | 5 | 2018 | 504 | 0.450 |
Why?
|
| Total Quality Management | 3 | 2008 | 30 | 0.420 |
Why?
|
| Reproducibility of Results | 10 | 2013 | 394 | 0.420 |
Why?
|
| Physician-Patient Relations | 6 | 2016 | 202 | 0.380 |
Why?
|
| Professional Practice | 1 | 2010 | 17 | 0.370 |
Why?
|
| Longitudinal Studies | 4 | 2010 | 705 | 0.340 |
Why?
|
| Continental Population Groups | 3 | 2018 | 317 | 0.340 |
Why?
|
| Insurance Claim Review | 6 | 2016 | 69 | 0.330 |
Why?
|
| Medication Adherence | 4 | 2013 | 255 | 0.330 |
Why?
|
| Adult | 29 | 2021 | 7696 | 0.330 |
Why?
|
| Chronic Disease | 8 | 2016 | 462 | 0.330 |
Why?
|
| Data Interpretation, Statistical | 5 | 2010 | 79 | 0.320 |
Why?
|
| Health Services Accessibility | 8 | 2018 | 316 | 0.300 |
Why?
|
| Massachusetts | 7 | 2013 | 100 | 0.300 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 35 | 0.300 |
Why?
|
| Osteoporosis | 3 | 2013 | 87 | 0.300 |
Why?
|
| Breast Neoplasms | 8 | 2011 | 1023 | 0.300 |
Why?
|
| Treatment Outcome | 9 | 2021 | 1259 | 0.290 |
Why?
|
| Medical Order Entry Systems | 2 | 2021 | 15 | 0.280 |
Why?
|
| Clinical Competence | 3 | 2012 | 109 | 0.280 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 1956 | 0.280 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 1346 | 0.270 |
Why?
|
| Patient Satisfaction | 7 | 2015 | 233 | 0.270 |
Why?
|
| Insurance, Health | 5 | 2016 | 221 | 0.260 |
Why?
|
| Bias | 4 | 2010 | 109 | 0.260 |
Why?
|
| Needs Assessment | 3 | 2019 | 73 | 0.240 |
Why?
|
| Colorectal Neoplasms | 5 | 2016 | 643 | 0.240 |
Why?
|
| Referral and Consultation | 3 | 2015 | 178 | 0.240 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 1255 | 0.240 |
Why?
|
| California | 8 | 2023 | 2327 | 0.240 |
Why?
|
| Quality of Life | 4 | 2016 | 509 | 0.230 |
Why?
|
| Goals | 1 | 2003 | 29 | 0.230 |
Why?
|
| Health Services Needs and Demand | 2 | 2019 | 112 | 0.230 |
Why?
|
| Anticoagulants | 2 | 2022 | 122 | 0.230 |
Why?
|
| Communication | 3 | 2016 | 205 | 0.220 |
Why?
|
| Censuses | 1 | 2023 | 32 | 0.220 |
Why?
|
| Insulin | 1 | 2024 | 208 | 0.220 |
Why?
|
| Medical Oncology | 3 | 2015 | 33 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 328 | 0.220 |
Why?
|
| Income | 1 | 2023 | 95 | 0.220 |
Why?
|
| Ambulatory Care | 3 | 2013 | 274 | 0.220 |
Why?
|
| Independent Practice Associations | 2 | 2017 | 8 | 0.210 |
Why?
|
| Young Adult | 10 | 2021 | 2479 | 0.210 |
Why?
|
| Prognosis | 1 | 2024 | 619 | 0.210 |
Why?
|
| Naloxone | 1 | 2022 | 19 | 0.210 |
Why?
|
| Indians, North American | 1 | 2022 | 50 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 178 | 0.210 |
Why?
|
| Cross-Sectional Studies | 9 | 2021 | 1309 | 0.210 |
Why?
|
| Blood Glucose | 1 | 2024 | 344 | 0.210 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 257 | 0.200 |
Why?
|
| Medical Audit | 4 | 2009 | 40 | 0.200 |
Why?
|
| Algorithms | 3 | 2016 | 235 | 0.200 |
Why?
|
| Cohort Studies | 12 | 2022 | 2631 | 0.200 |
Why?
|
| Patient Discharge | 1 | 2023 | 150 | 0.200 |
Why?
|
| Benchmarking | 5 | 2017 | 45 | 0.200 |
Why?
|
| Cephalosporins | 1 | 2021 | 8 | 0.200 |
Why?
|
| Drug Hypersensitivity | 1 | 2021 | 10 | 0.200 |
Why?
|
| Penicillins | 1 | 2021 | 7 | 0.200 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 526 | 0.200 |
Why?
|
| Bioprosthesis | 1 | 2021 | 2 | 0.200 |
Why?
|
| Heart Valves | 1 | 2021 | 4 | 0.200 |
Why?
|
| Bone Density Conservation Agents | 2 | 2012 | 55 | 0.190 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 19 | 0.190 |
Why?
|
| Adolescent | 13 | 2021 | 3714 | 0.190 |
Why?
|
| Fractures, Bone | 2 | 2012 | 91 | 0.190 |
Why?
|
| Florida | 2 | 2019 | 8 | 0.190 |
Why?
|
| Hypokalemia | 1 | 2020 | 3 | 0.180 |
Why?
|
| Warfarin | 1 | 2021 | 74 | 0.180 |
Why?
|
| Hospital Mortality | 4 | 2022 | 150 | 0.180 |
Why?
|
| Cost Control | 3 | 2010 | 27 | 0.180 |
Why?
|
| Hyperkalemia | 1 | 2020 | 21 | 0.180 |
Why?
|
| Quality Improvement | 2 | 2013 | 205 | 0.180 |
Why?
|
| Patient Navigation | 1 | 2019 | 17 | 0.180 |
Why?
|
| Data Collection | 4 | 2014 | 276 | 0.180 |
Why?
|
| Social Work | 1 | 2019 | 14 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 138 | 0.170 |
Why?
|
| Ophthalmology | 3 | 2003 | 6 | 0.170 |
Why?
|
| Fee-for-Service Plans | 2 | 2016 | 28 | 0.170 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 166 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 40 | 0.170 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 164 | 0.170 |
Why?
|
| Pseudophakia | 1 | 2018 | 2 | 0.170 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2018 | 2 | 0.170 |
Why?
|
| Cataract Extraction | 1 | 2018 | 3 | 0.170 |
Why?
|
| Visual Acuity | 1 | 2018 | 20 | 0.170 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 65 | 0.160 |
Why?
|
| Women's Health Services | 1 | 2018 | 21 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2019 | 96 | 0.160 |
Why?
|
| Heart Failure | 3 | 2015 | 391 | 0.160 |
Why?
|
| Workload | 1 | 2018 | 31 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 2 | 2009 | 77 | 0.160 |
Why?
|
| Preventive Health Services | 5 | 2009 | 164 | 0.160 |
Why?
|
| Diabetic Retinopathy | 3 | 2018 | 19 | 0.160 |
Why?
|
| Stroke | 1 | 2021 | 306 | 0.160 |
Why?
|
| Intensive Care Units | 2 | 2018 | 103 | 0.150 |
Why?
|
| Efficiency, Organizational | 1 | 2017 | 37 | 0.150 |
Why?
|
| Critical Care | 1 | 2018 | 72 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 439 | 0.150 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 227 | 0.150 |
Why?
|
| Socioeconomic Factors | 9 | 2015 | 667 | 0.150 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 20 | 0.150 |
Why?
|
| Logistic Models | 6 | 2013 | 953 | 0.150 |
Why?
|
| Patient-Centered Care | 2 | 2012 | 228 | 0.150 |
Why?
|
| Time Factors | 5 | 2015 | 1114 | 0.140 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 16 | 0.140 |
Why?
|
| Guideline Adherence | 3 | 2008 | 160 | 0.140 |
Why?
|
| Electronic Health Records | 3 | 2022 | 734 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2018 | 290 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 24 | 0.130 |
Why?
|
| Age Factors | 6 | 2015 | 945 | 0.120 |
Why?
|
| Job Satisfaction | 1 | 2014 | 20 | 0.120 |
Why?
|
| Group Practice | 3 | 2010 | 25 | 0.120 |
Why?
|
| Self Care | 1 | 2015 | 175 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 195 | 0.120 |
Why?
|
| Testosterone | 1 | 2014 | 22 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 7 | 0.120 |
Why?
|
| Rectum | 1 | 2013 | 12 | 0.120 |
Why?
|
| Colon | 1 | 2013 | 21 | 0.120 |
Why?
|
| Comorbidity | 4 | 2013 | 618 | 0.120 |
Why?
|
| Diskectomy | 1 | 2013 | 2 | 0.120 |
Why?
|
| Hospitals, Special | 1 | 2013 | 2 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2013 | 2 | 0.120 |
Why?
|
| Spinal Fusion | 1 | 2013 | 5 | 0.120 |
Why?
|
| Prescription Drugs | 1 | 2014 | 32 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 552 | 0.110 |
Why?
|
| Optometry | 2 | 2003 | 2 | 0.110 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2003 | 9 | 0.110 |
Why?
|
| Practice Management, Medical | 2 | 2003 | 17 | 0.110 |
Why?
|
| African Americans | 5 | 2018 | 485 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2012 | 595 | 0.110 |
Why?
|
| Colectomy | 1 | 2013 | 27 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2013 | 9 | 0.110 |
Why?
|
| Health Surveys | 6 | 2013 | 266 | 0.110 |
Why?
|
| Health Care Surveys | 7 | 2008 | 252 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2013 | 17 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 70 | 0.110 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2013 | 106 | 0.110 |
Why?
|
| Private Practice | 2 | 2010 | 15 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2022 | 60 | 0.110 |
Why?
|
| Social Class | 1 | 2013 | 125 | 0.110 |
Why?
|
| Linear Models | 4 | 2014 | 240 | 0.100 |
Why?
|
| Utilization Review | 2 | 2010 | 54 | 0.100 |
Why?
|
| Sex Factors | 4 | 2018 | 634 | 0.100 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 24 | 0.100 |
Why?
|
| Alprazolam | 1 | 2011 | 1 | 0.100 |
Why?
|
| Diazepam | 1 | 2011 | 1 | 0.100 |
Why?
|
| Joint Dislocations | 1 | 2011 | 2 | 0.100 |
Why?
|
| Lorazepam | 1 | 2011 | 4 | 0.100 |
Why?
|
| Pyridines | 1 | 2011 | 10 | 0.100 |
Why?
|
| State Health Plans | 1 | 2012 | 43 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 251 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 17 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 41 | 0.100 |
Why?
|
| Patient Care Management | 1 | 2011 | 31 | 0.100 |
Why?
|
| Commerce | 2 | 2009 | 49 | 0.100 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2011 | 28 | 0.100 |
Why?
|
| Selection Bias | 2 | 2008 | 24 | 0.100 |
Why?
|
| Oregon | 2 | 2008 | 195 | 0.100 |
Why?
|
| Hip Fractures | 1 | 2011 | 70 | 0.100 |
Why?
|
| Diphosphonates | 1 | 2012 | 64 | 0.100 |
Why?
|
| Mastectomy | 2 | 2008 | 36 | 0.090 |
Why?
|
| Drug Prescriptions | 2 | 2010 | 157 | 0.090 |
Why?
|
| Taxes | 1 | 2010 | 19 | 0.090 |
Why?
|
| Cystectomy | 1 | 2010 | 8 | 0.090 |
Why?
|
| Patient Participation | 2 | 2008 | 143 | 0.090 |
Why?
|
| Hispanic Americans | 4 | 2018 | 431 | 0.090 |
Why?
|
| Electronic Prescribing | 1 | 2010 | 6 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 2 | 2007 | 33 | 0.090 |
Why?
|
| Diagnosis-Related Groups | 1 | 2010 | 31 | 0.090 |
Why?
|
| Interview, Psychological | 1 | 2010 | 19 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 393 | 0.090 |
Why?
|
| Postoperative Complications | 4 | 2013 | 101 | 0.090 |
Why?
|
| European Continental Ancestry Group | 4 | 2018 | 559 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2010 | 43 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 49 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 60 | 0.090 |
Why?
|
| Educational Status | 2 | 2023 | 205 | 0.080 |
Why?
|
| Pregnancy | 1 | 2014 | 1484 | 0.080 |
Why?
|
| Medical Records | 2 | 2007 | 108 | 0.080 |
Why?
|
| Mammaplasty | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 264 | 0.080 |
Why?
|
| Motivation | 1 | 2010 | 133 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 16 | 0.080 |
Why?
|
| Physicians, Family | 1 | 2009 | 48 | 0.080 |
Why?
|
| Sample Size | 1 | 2008 | 29 | 0.080 |
Why?
|
| Physician Incentive Plans | 1 | 2008 | 9 | 0.080 |
Why?
|
| Probability | 1 | 2008 | 86 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2008 | 162 | 0.080 |
Why?
|
| Office Visits | 1 | 2008 | 85 | 0.080 |
Why?
|
| Health Promotion | 1 | 2010 | 295 | 0.080 |
Why?
|
| Affect | 1 | 2007 | 26 | 0.070 |
Why?
|
| Adolescent Health Services | 1 | 2007 | 43 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2011 | 692 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 92 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2013 | 270 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2007 | 60 | 0.070 |
Why?
|
| Child Health Services | 1 | 2007 | 128 | 0.070 |
Why?
|
| Depression | 1 | 2011 | 512 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2006 | 24 | 0.070 |
Why?
|
| Demography | 3 | 2013 | 106 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 324 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 330 | 0.070 |
Why?
|
| Health Services for the Aged | 1 | 2005 | 15 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2008 | 357 | 0.060 |
Why?
|
| Patients | 2 | 2016 | 39 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2005 | 66 | 0.060 |
Why?
|
| Survival Rate | 1 | 2005 | 266 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 303 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 163 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2019 | 1294 | 0.060 |
Why?
|
| Efficiency | 1 | 2003 | 13 | 0.060 |
Why?
|
| Asthma | 1 | 2006 | 302 | 0.060 |
Why?
|
| Prepaid Health Plans | 1 | 2003 | 22 | 0.060 |
Why?
|
| Glaucoma | 1 | 2003 | 11 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2003 | 84 | 0.060 |
Why?
|
| Hospital Bed Capacity | 2 | 2013 | 7 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2003 | 97 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2004 | 225 | 0.060 |
Why?
|
| Contract Services | 1 | 2002 | 4 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2022 | 10 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 11 | 0.050 |
Why?
|
| Diphenhydramine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Anti-Allergic Agents | 1 | 2002 | 1 | 0.050 |
Why?
|
| Histamine H1 Antagonists | 1 | 2002 | 3 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 51 | 0.050 |
Why?
|
| Spinal Cord Injuries | 1 | 2002 | 5 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2002 | 13 | 0.050 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 481 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2002 | 20 | 0.050 |
Why?
|
| Primary Health Care | 2 | 2010 | 843 | 0.050 |
Why?
|
| Patient Care | 1 | 2021 | 37 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 56 | 0.050 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 6 | 0.050 |
Why?
|
| Risk | 2 | 2014 | 552 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2023 | 248 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2021 | 81 | 0.050 |
Why?
|
| Potassium | 1 | 2020 | 20 | 0.050 |
Why?
|
| Child | 4 | 2009 | 2519 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2006 | 318 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2012 | 330 | 0.050 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2019 | 3 | 0.040 |
Why?
|
| Los Angeles | 2 | 2011 | 140 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 238 | 0.040 |
Why?
|
| Health Status | 2 | 2015 | 331 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 43 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 3 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 16 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1164 | 0.040 |
Why?
|
| Neoplasms | 2 | 2014 | 464 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 454 | 0.040 |
Why?
|
| SEER Program | 2 | 2010 | 100 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2018 | 69 | 0.040 |
Why?
|
| Health Services | 2 | 2012 | 111 | 0.040 |
Why?
|
| Nurses | 1 | 2018 | 34 | 0.040 |
Why?
|
| Social Support | 1 | 2019 | 211 | 0.040 |
Why?
|
| Reimbursement, Incentive | 1 | 2017 | 30 | 0.040 |
Why?
|
| Observation | 2 | 2008 | 25 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2017 | 31 | 0.040 |
Why?
|
| Risk Factors | 3 | 2012 | 3394 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2017 | 80 | 0.030 |
Why?
|
| Germany | 1 | 2016 | 13 | 0.030 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2016 | 6 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2016 | 25 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2015 | 2 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 72 | 0.030 |
Why?
|
| Burnout, Professional | 1 | 2015 | 16 | 0.030 |
Why?
|
| Terminal Care | 1 | 2015 | 37 | 0.030 |
Why?
|
| Infant | 2 | 2009 | 1212 | 0.030 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2016 | 248 | 0.030 |
Why?
|
| Tadalafil | 1 | 2014 | 2 | 0.030 |
Why?
|
| Carbolines | 1 | 2014 | 2 | 0.030 |
Why?
|
| Sulfones | 1 | 2014 | 3 | 0.030 |
Why?
|
| Purines | 1 | 2014 | 3 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2009 | 1428 | 0.030 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sildenafil Citrate | 1 | 2014 | 4 | 0.030 |
Why?
|
| Piperazines | 1 | 2014 | 9 | 0.030 |
Why?
|
| Asian Americans | 1 | 2015 | 184 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 166 | 0.030 |
Why?
|
| Netherlands | 1 | 2013 | 7 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2013 | 13 | 0.030 |
Why?
|
| Pharmacies | 1 | 2013 | 10 | 0.030 |
Why?
|
| Hospital Charges | 1 | 2013 | 8 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2013 | 34 | 0.030 |
Why?
|
| Quality Control | 1 | 2012 | 45 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 116 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2013 | 89 | 0.030 |
Why?
|
| Preferred Provider Organizations | 1 | 2011 | 2 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2012 | 120 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 892 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2012 | 81 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2011 | 65 | 0.020 |
Why?
|
| Cost Sharing | 1 | 2011 | 40 | 0.020 |
Why?
|
| Influenza Vaccines | 2 | 2004 | 284 | 0.020 |
Why?
|
| American Hospital Association | 1 | 2010 | 2 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2011 | 130 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 113 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 215 | 0.020 |
Why?
|
| Cost Savings | 1 | 2010 | 25 | 0.020 |
Why?
|
| New Jersey | 1 | 2010 | 7 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 11 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 57 | 0.020 |
Why?
|
| Attitude to Computers | 1 | 2010 | 16 | 0.020 |
Why?
|
| Medical Record Linkage | 1 | 2010 | 43 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 83 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 97 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 127 | 0.020 |
Why?
|
| Fees, Medical | 1 | 2009 | 5 | 0.020 |
Why?
|
| Ownership | 1 | 2009 | 15 | 0.020 |
Why?
|
| Social Responsibility | 1 | 2008 | 9 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2008 | 28 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2008 | 55 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2008 | 77 | 0.020 |
Why?
|
| Family Practice | 1 | 2008 | 58 | 0.020 |
Why?
|
| Nausea | 1 | 2007 | 7 | 0.020 |
Why?
|
| Vomiting | 1 | 2007 | 11 | 0.020 |
Why?
|
| Women, Working | 1 | 2007 | 6 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 18 | 0.020 |
Why?
|
| Marital Status | 1 | 2007 | 22 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 79 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2007 | 40 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2007 | 126 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2007 | 97 | 0.020 |
Why?
|
| Diagnosis | 1 | 2006 | 5 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2006 | 51 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 249 | 0.020 |
Why?
|
| Washington | 1 | 2007 | 384 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 21 | 0.020 |
Why?
|
| Urban Population | 1 | 2006 | 122 | 0.020 |
Why?
|
| Pediatrics | 1 | 2007 | 164 | 0.020 |
Why?
|
| Life Tables | 1 | 2005 | 11 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2006 | 134 | 0.020 |
Why?
|
| Empirical Research | 1 | 2004 | 2 | 0.010 |
Why?
|
| Pacific States | 1 | 2003 | 2 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 77 | 0.010 |
Why?
|
| Filtering Surgery | 1 | 2003 | 1 | 0.010 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2003 | 1 | 0.010 |
Why?
|
| Visual Fields | 1 | 2003 | 4 | 0.010 |
Why?
|
| Program Development | 1 | 2004 | 78 | 0.010 |
Why?
|
| Intraocular Pressure | 1 | 2003 | 9 | 0.010 |
Why?
|
| Models, Econometric | 1 | 2003 | 11 | 0.010 |
Why?
|
| Capitation Fee | 1 | 2002 | 12 | 0.010 |
Why?
|
| Financial Management | 1 | 2002 | 3 | 0.010 |
Why?
|
| Loratadine | 1 | 2002 | 1 | 0.010 |
Why?
|
| Motor Skills | 1 | 2002 | 2 | 0.010 |
Why?
|
| Forecasting | 1 | 2003 | 77 | 0.010 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2002 | 1 | 0.010 |
Why?
|
| Bacteriuria | 1 | 2002 | 3 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 170 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 745 | 0.010 |
Why?
|